HeyJaredXinmei Shen
- Indexed articles, last 90 days
- 45
- Latest publication
- Sep 26, 2026
- Outlet visibility, for South China Morning Post
- Top 50K sites
- Earliest in this view
- Jul 7, 2026
Latest articles
How Chinese biotech is graduating from licensing deals to broader partnerships (opens the original)
Read excerpt
InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion. InnoCare said it would use its drug discovery platform to identify and advance compo
How FDA backing could advance multi-cancer blood tests despite Hong Kong doubts (opens the original)
Read excerpt
Doctors say more data is needed despite growing interest in detecting multiple cancers from a single blood sample In a landmark decision for the emerging field of multi-cancer early detection (MCED) blood tests, a US Food and Drug Administration (FDA) panel on Thursday voted in favour of US company Grail’s “Galleri test”, recommending it for premarket approval. MCED tests seek to identify signs of cancer in healthy, asymptomatic individuals by analysing abnormal molecules, including circulating
Are clinical trials about to become a new front in the US-China biotech race? (opens the original)
Read excerpt
China’s ability to conduct clinical trials quickly and cheaply has given it an edge in the biotech sector – and the US is growing concerned China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts. US lawmakers and officials at the Food and Drug Administration (FDA) have raised the alarm about American pharmaceutical com
Biomedicine powerhouse: China targets quarter of global first-in-class drugs (opens the original)
Read excerpt
New five-year plan aims to turn the sector into a pillar industry by 2030, driven by breakthroughs in technologies across critical fields China has set its sights on becoming a global biomedicine powerhouse by 2030, targeting key technological breakthroughs and at least a quarter of the world’s first-in-class drugs market under a new five-year plan for the sector. The plan sets 10 measurable targets, including requiring large pharmaceutical enterprises to generate combined revenue of no less tha
From US Fed rates to China’s global export share: 4 figures shaping markets (opens the original)
Read excerpt
The US central bank raised rates for first time since 2023, Hong Kong followed and Goldman Sachs projects a sharp rise in Chinese firms’ global export share The US Federal Reserve raised its benchmark interest rate by a quarter of a percentage point this week, followed by the Hong Kong Monetary Authority and the Bank of Japan, while the 10-year US Treasury yield fell back below 5 per cent. Here are some of the figures that have drawn the most market attention this week. Following the Fed’s annou
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For South China Morning Post, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.